Sumitomo Mitsui Trust Group
NTLA icon

Sumitomo Mitsui Trust Group’s Intellia Therapeutics NTLA Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49M Buy
2,897,529
+924,468
+47% +$12.9M 0.03% 461
2026
Q1 		$25.3M Sell
1,973,061
-219,400
-10% -$2.79M 0.02% 591
2025
Q4 		$19.7M Sell
2,192,461
-162,395
-7% -$2.24M 0.01% 639
2025
Q3 		$40.7M Sell
2,354,856
-316,409
-12% -$3.9M 0.02% 523
2025
Q2 		$25.1M Sell
2,671,265
-154,096
-5% -$1.27M 0.02% 613
2025
Q1 		$20.1M Sell
2,825,361
-167,302
-6% -$1.69M 0.01% 638
2024
Q4 		$34.9M Sell
2,992,663
-156,736
-5% -$2.45M 0.02% 543
2024
Q3 		$64.7M Sell
3,149,399
-108,290
-3% -$2.5M 0.04% 385
2024
Q2 		$72.9M Sell
3,257,689
-141,629
-4% -$3.37M 0.05% 344
2024
Q1 		$93.5M Sell
3,399,318
-79,244
-2% -$2.2M 0.06% 316
2023
Q4 		$106M Sell
3,478,562
-41,733
-1% -$1.2M 0.08% 269
2023
Q3 		$111M Buy
3,520,295
+125,639
+4% +$4.87M 0.09% 228
2023
Q2 		$138M Buy
3,394,656
+281,692
+9% +$11.4M 0.11% 190
2023
Q1 		$116M Buy
3,112,964
+136,962
+5% +$5.37M 0.09% 253
2022
Q4 		$104M Buy
2,976,002
+12,074
+0.4% +$574K 0.08% 280
2022
Q3 		$166M Buy
2,963,928
+182,792
+7% +$11.3M 0.14% 169
2022
Q2 		$144M Sell
2,781,136
-91,133
-3% -$4.63M 0.11% 207
2022
Q1 		$209M Buy
2,872,269
+118,366
+4% +$10M 0.14% 154
2021
Q4 		$326M Buy
2,753,903
+353,970
+15% +$44.3M 0.2% 112
2021
Q3 		$322M Sell
2,399,933
-727,670
-23% -$110M 0.2% 109
2021
Q2 		$506M Sell
3,127,603
-1,679,691
-35% -$131M 0.3% 74
2021
Q1 		$386M Sell
4,807,294
-297,068
-6% -$19.9M 0.24% 90
2020
Q4 		$278M Sell
5,104,362
-958,154
-16% -$34.8M 0.18% 128
2020
Q3 		$121M Sell
6,062,516
-132,673
-2% -$2.77M 0.08% 261
2020
Q2 		$130M Sell
6,195,189
-896,074
-13% -$15.2M 0.09% 234
2020
Q1 		$86.7M Sell
7,091,263
-87,257
-1% -$1.18M 0.07% 287
2019
Q4 		$105M Sell
7,178,520
-61,217
-0.8% -$852K 0.08% 255
2019
Q3 		$96.7M Buy
7,239,737
+5,023,077
+227% +$80.1M 0.08% 256
2019
Q2 		$36.3M Buy
2,216,660
+1,169,968
+112% +$18.4M 0.03% 533
2019
Q1 		$17.9M Buy
+1,046,692
New +$15.6M 0.02% 650

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Sumitomo Mitsui Trust Group's NTLA Position: Q2 2026 in Review

Sumitomo Mitsui Trust Group increased its Intellia Therapeutics (NTLA) stake by 47% in Q2 2026, buying an estimated $12.9M and bringing the position to 2,897,529 shares worth $49M. The position accounts for 0.03% of the portfolio, ranked #461.

Sumitomo Mitsui Trust Group first reported a position in NTLA in Q1 2019 and has held it in 30 quarters since. The position peaked at $506M in Q2 2021. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Sumitomo Mitsui Trust Group held 2,897,529 shares of Intellia Therapeutics worth $49M as of Q2 2026.
  • Sumitomo Mitsui Trust Group bought 924,468 Intellia Therapeutics shares in Q2 2026, an estimated $12.9M.
  • Intellia Therapeutics made up 0.03% of Sumitomo Mitsui Trust Group's portfolio in Q2 2026, its #461 holding.
  • Sumitomo Mitsui Trust Group first reported a position in Intellia Therapeutics in Q1 2019 and has held it in 30 quarters since.
  • Sumitomo Mitsui Trust Group's Intellia Therapeutics position peaked at $506M in Q2 2021.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q2 2026, filed 30 Jul 2026.